Tevogen Inc.
For the period ended Aug 3, 2026. Filed Aug 3, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Aug 3, 2026 · Filed Aug 3, 2026
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
|---|---|
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☒ | Definitive Proxy Statement |
| ☐ | Definitive Additional Materials |
| ☐ | Soliciting Material under §240.14a-12 |
Tevogen Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☒ | No fee required |
|---|---|
| ☐ | Fee paid previously with preliminary materials |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
TEVOGEN INC.
15 Independence Boulevard, Suite #210
Warren, New Jersey
NOTICE OF 2026 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD AT 1:30 p.m. EASTERN TIME ON AUGUST 24, 2026
MEETING LOCATION:
www.virtualshareholdermeeting.com/TVGN2026
Dear Tevogen Inc. Stockholder:
You are cordially invited to attend the 2026 Annual Meeting of the Stockholders (the “Annual Meeting”) of Tevogen Inc., formerly known as Tevogen Bio Holdings Inc. (the “Company”). The Annual Meeting will be held on August 24, 2026, commencing at 1:30 p.m. Eastern Time, and will be a completely virtual meeting of stockholders.
The items of business for the Annual Meeting are to:
| 1. | Elect as Class II directors the two nominees named in the attached proxy statement to serve for a term of three years each, or until their respective successors are duly elected and qualified. |
The Board of Directors recommends that you voteFOR the election of each director nominee.
| 2. | Ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. |
The Board of Directors recommends that you voteFOR Proposal 2.
| 3. | Approve an amendment to the Tevogen 2024 Omnibus Incentive Plan, as amended (the “2024 Plan”) to increase the number of shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), available for issuance thereunder by 100,000,000 (the “2024 Plan Amendment”). |
The Board of Directors recommends that you voteFOR Proposal 3.
| 4. | Approve an amendment to the Certificate of Incorporation of the Company, as amended (the “Charter”), to permit stockholder action by written consent (the “Written Consent Charter Amendment”). |
The Board of Directors recommends that you voteFOR Proposal 4.
We will also transact any other business as may properly come before the meeting or any adjournment or postponement thereof.
The Annual Meeting will be held only via live webcast. We believe that the virtual meeting format expands stockholder access and participation and improves communications.
You will be able to attend and participate in the Annual Meeting online, vote your shares electronically, and submit your questions prior to and during the meeting by visiting:www.virtualshareholdermeeting.com/TVGN2026. To vote at the meeting, you must have your control number that is shown on your Notice of Internet Availability of Proxy Materials (“Notice”), voting instruction form, or proxy card. We encourage you to access the Annual Meeting prior to the start time to allow ample time for online check-in. The website will be open for check-in beginning at 1:15 p.m. Eastern Time on the date of the Annual Meeting.
Only stockholders of record at the close of business on July 23, 2026 are entitled to notice of and to vote at the Annual Meeting. Any person who was not a stockholder as of the record date may attend the Annual Meeting as an observer but will not be able to vote or ask questions.
We encourage you to attend the Annual Meeting, but it is important that your shares are represented at the Annual Meeting whether or not you plan to attend. To ensure that you will be represented, we ask you to vote online, by mail, or by phone as soon as possible, using one of the methods below.
We expect to commence mailing these proxy materials to our security holders on or about August 3, 2026.
Your Vote is Important
We encourage all stockholders of record to read the attached proxy statement with care and vote right away using any of the following methods, even if they intend to attend the Annual Meeting. If you plan to vote during the Annual Meeting, you may do so if you enter your “control number.” The control number is a 16-digit number that you can find in your voting instruction form (if you are a beneficial owner who received proxy materials by mail) or proxy card (if you are a stockholder of record who received proxy materials by mail), as applicable, at the time you log into the meeting atwww.virtualshareholdermeeting.com/TVGN2026. Please note, however, that if your shares are held of record by a broker, bank, or other nominee and you wish to vote at the meeting, you may need to obtain a proxy issued in your name from that record holder. Please contact your broker, bank, or other nominee for information about specific requirements if you would like to vote your shares at the meeting.
To vote online atwww.proxyvote.com, have the 16-digit control number available and then follow the instructions. Beneficial owners who do not have a control number should follow the instructions provided on the voting instruction card or otherwise provided by your bank, broker or other nominee.
| Online | www.proxyvote.com |
|---|---|
| By Phone | In the U.S. or Canada dial toll-free (800) 690-6903 |
| By Mail | Cast your ballot, sign your proxy card, and send in our prepaid envelope |
Tevogen Inc.
By order of the Board of Directors,
Dr. Ryan Saadi
Chairperson of the Board of Directors, Director, and Chief Executive Officer
Warren, New Jersey, USA
August 3, 2026
Table of Contents
| Cautionary Note Regarding Forward-Looking Statements | 1 |
|---|---|
| Proxy Summary | 2 |
| About Tevogen | 2 |
| Voting Matters and Board Recommendations | 2 |
| How to Vote | 2 |
| Proposal No. 1 - Election of Directors | 3 |
| Board of Directors | 3 |
| Directors and Nominees | 3 |
| Corporate Governance | 5 |
| Composition of the Board | 5 |
| Director Qualifications | 5 |
| Director Independence | 5 |
| Board Leadership Structure | 5 |
| Role of Board in Risk Oversight | 6 |
| Controlled Company Status | 6 |
| Board Meetings and Committees | 6 |
| Nomination of Directors | 8 |
| Code of Business Conduct and Ethics | 8 |
| Insider Trading Policy | 8 |
| Communications with the Board of Directors | 8 |
| Certain Relationships and Related Person Transactions | 8 |
| Security Ownership of Certain Beneficial Owners and Management | 12 |
| Director Compensation | 13 |
| Executive Compensation | 14 |
| Summary Compensation Table | 14 |
| Narrative Disclosure to Summary Compensation Table | 15 |
| Outstanding Equity Awards at Fiscal Year-End | 16 |
| Anti-Hedging and Anti-Pledging Policy | 16 |
| Policies and Practices Related to the Grant of Certain Equity Awards | 16 |
| Equity Compensation Plan Information | 16 |
| Proposal No. 2 - Ratification of Appointment of Independent Registered Public Accounting Firm | 17 |
| Audit Fees | 17 |
| Pre-Approval Policies and Procedures | 17 |
| Audit Committee Report | 18 |
| Proposal No. 3 - Amendment To the 2024 Plan to Increase the Number of Shares of Common Stock Available for Issuance | 19 |
| Background | 19 |
| Notable Features of the 2024 Plan | 19 |
| Summary of the Material Terms of the 2024 Plan | 20 |
| Certain Material U.S. Federal Income Tax Consequences | 25 |
| Plan Benefits | 28 |
| Explanation of Amendments | 28 |
| Proposal No. 4 - Approval of an Amendment to the Company’s Certificate of Incorporation to Permit Stockholders to Act by Written Consent In Lieu of a Meeting | 29 |
| Background | 29 |
| Reasons for the Written Consent Charter Amendment | 29 |
| Interests of the Controlling Stockholder | 30 |
| Effectiveness of the Written Consent Charter Amendment if Approved | 30 |
| Questions and Answers | 31 |
| Additional Information | 35 |
| Stockholder Proposals to be Included in Next Year’s Proxy Statement | 35 |
| Stockholder Nominations and Proposals to be Brought Before Next Year’s Annual Meeting | 35 |
| Householding | 36 |
| Other Business | 36 |
| Availability of Proxy Materials | 36 |
| Annex A: 2024 Plan Amendment | A-1 |
| Annex B: Certificate of Amendment to the Certificate of Incorporation of Tevogen Inc. | B-1 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.